Celldex Therapeutics, Inc. (CLDX)

NASDAQ: CLDX · Real-Time Price · USD

40.38

+0.44 (1.10%)

At close: Aug 21, 2026, 4:00 PM EDT

40.41

+0.03 (0.07%)

After-hours: Aug 21, 2026, 7:30 PM EDT

Celldex Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	47.45	28.87	28.36	34.81	29.43	39.14
Short-Term Investments	670.13	489.7	696.93	388.78	275.52	369.11
Cash & Short-Term Investments	717.59	518.57	725.28	423.6	304.95	408.25
Cash Growth	13.84%	-28.50%	71.22%	38.91%	-25.30%	109.98%
Receivables	0.23	2.02	0.7	2.63	0.35	0.17
Prepaid Expenses	7.11	14.08	21.18	5.47	12.39	2.42
Total Current Assets	724.93	534.66	747.16	431.69	317.69	410.84
Property, Plant & Equipment	14.79	7.77	8.24	6.64	7.75	6.52
Other Intangible Assets	27.19	27.19	27.19	27.19	27.19	27.19
Other Long-Term Assets	15.43	13.36	9.75	0.11	0.1	0.1
Total Assets	782.35	582.98	792.34	465.63	352.74	444.65

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	14.68	1.18	3.27	3.49	3.34	1.23
Accrued Expenses	43.86	47.03	33.84	22.03	12.84	12
Current Portion of Leases	1.56	1.55	1.45	1.61	1.45	1.75
Current Unearned Revenue	-	1.23	0.01	3.06	0.06	0.43
Other Current Liabilities	1.23	-	0.93	0.93	0.93	1.12
Total Current Liabilities	61.33	50.99	39.5	31.13	18.61	16.53
Long-Term Leases	3.35	0.78	2.36	0.93	2.59	1.3
Long-Term Unearned Revenue	-	2.43	-	-	-	-
Long-Term Deferred Tax Liabilities	-	1.61	-	-	-	-
Other Long-Term Liabilities	3.11	-	3.47	4.4	5.33	7.35
Total Liabilities	67.79	55.82	45.34	36.46	26.53	25.18

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.08	0.07	0.07	0.06	0.05	0.05
Additional Paid-In Capital	2,679	2,337	2,299	1,823	1,581	1,561
Retained Earnings	-1,966	-1,814	-1,555	-1,397	-1,256	-1,144
Comprehensive Income & Other	1.3	3.63	3.31	3.31	1.26	1.89
Shareholders' Equity	714.56	527.17	747.01	429.17	326.2	419.48
Total Liabilities & Equity	782.35	582.98	792.34	465.63	352.74	444.65

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	4.9	2.34	3.81	2.54	4.03	3.04
Net Cash (Debt)	712.68	516.24	721.47	421.06	300.92	405.21
Net Cash Growth	13.61%	-28.45%	71.35%	39.92%	-25.74%	112.22%
Net Cash Per Share	10.28	7.77	11.20	8.69	6.42	9.45
Filing Date Shares Outstanding	78.53	66.57	66.38	55.9	47.21	46.74
Total Common Shares Outstanding	78.5	66.55	66.37	55.88	47.2	46.73
Working Capital	663.61	483.67	707.66	400.57	299.08	394.31
Book Value Per Share	9.10	7.92	11.25	7.68	6.91	8.98
Tangible Book Value	687.37	499.98	719.82	401.98	299.01	392.29
Tangible Book Value Per Share	8.76	7.51	10.84	7.19	6.33	8.39
Machinery	-	17.18	17.39	16.01	15.26	14.51
Construction In Progress	-	1.72	0.14	0.79	0.5	0.63
Leasehold Improvements	-	10.34	10.29	9.65	9.61	9.53

SEC Filings: 10-K · 10-Q